Pfizer CEO sees drug rebates ‘going away’ in US
Pfizer CEO Ian Read believes the U.S. will eventually have a system without drug rebates, especially considering the Trump administration’s proposed plan to restrict these kickback exemptions. This comes several weeks after President Trump confronted Pfizer over price hikes on its products.
Read’s comments are a notable sign of support from Big Pharma for major changes to how drugs are paid for in the U.S. The pharma industry has frequently blamed rebates as a major factor in rising prescription drug costs, claiming that providing discounts to insurers forces companies to increase list prices.
